کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
3339295 | 1213905 | 2014 | 7 صفحه PDF | دانلود رایگان |
![عکس صفحه اول مقاله: Hepatitis C Virus Treatment in the ‘Real-World’: How Well Do ‘Real’ Patients Respond? Hepatitis C Virus Treatment in the ‘Real-World’: How Well Do ‘Real’ Patients Respond?](/preview/png/3339295.png)
BackgroundPublished clinical trials of the treatment of HCV are largely multicentre prospective pharmaceutical trials. Patients in clinical trials tend to have more favorable outcomes than patients in the ‘real-world’, due to strict patient selection and differences in treatment conditions and available resources.ObjectivesTo assess the outcomes of Hepatitis C infected patients treated at the Barwon Health Liver Clinic with combination Pegylated interferon (PEG-IFN) and Ribavirin (RBV) therapy and to determine factors associated with a treatment response.MethodsRetrospective review of patients who received treatment for Hepatitis C at our institution's Liver Clinic from January 2001–September 2011. Patient demographics, comorbidities, treatment-related parameters and side effects were extracted from medical records and analyzed.ResultsA total of 190 patients (120 male, 70 female) with a mean age of 42.8 years (range 20–68 years) commenced treatment. The most common genotype was genotype 3 (48.9%), followed by genotype 1 (42.6%). 150 of 190 patients (78.9%) completed treatment and had end of treatment data available. 107 of 182 patients, (58.8%) for whom sustained virologic response (SVR) rate data was available achieved an SVR. Overall response rates were; 46.9%, 68.8% and 62.4% in genotypes 1, 2 and 3 respectively. The response rate was significantly lower in 29 patients with documented cirrhosis (20.7%). Age, diabetes and alcohol abuse did not predict treatment response in our cohort. Side effects reported in 81.6% of patients included general malaise, hematological disturbance and psychiatric issues, and necessitated cessation of therapy in 16 patients (8.4%) and dose reduction in 26 patients (13.7%).ConclusionsResponse rates to combination PEG-IFN and RBV therapy at our institution are comparable to other ‘real-world’ and pharmaceutical registration trials. Side effects of combination therapy were prominent but resulted in fewer discontinuations of therapy compared to pharmaceutical trials.
Journal: Journal of Clinical and Experimental Hepatology - Volume 4, Issue 3, September 2014, Pages 214–220